# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Hatshepsut (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC006-SYN
- Date: 2026-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Amunet Okafor-Harrington, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: healing after the extraction, diabetes, eye and foot screening, and cardiovascular risk. **S**

## History of present illness

Ms. Hatshepsut returns six weeks after the extraction. The socket healed without trouble and she finished the two weeks of chlorhexidine; she is chewing on both sides again. She takes metformin 1000 mg with the evening meal without stomach upset. Her thirst and night urination have eased. She has been to two of the diabetes education and nutrition sessions and has cut down on sweet tea and dates. She would like to lose some weight to make the stairs easier, and asks about the weekly injections she has read about. Her knees hurt less since she began the strengthening exercises and the gel. **S**

| Element | Detail |
|---|---|
| Mouth | Socket healed; chewing on both sides |
| Diabetes | Metformin 1000 mg tolerated; two education sessions; thirst eased |
| Her goal | Climb stairs at the sites more easily; interested in a GLP-1 medicine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy better |
| Ears, nose, mouth, and throat | Negative | No dental pain or swelling |
| Gastrointestinal | Negative | No nausea, diarrhea or abdominal pain |
| Musculoskeletal | Positive | Knee pain on stairs, better with exercises |
| Neurological | Negative | No numbness or tingling in the feet |

5 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg tablet, one tablet with the evening meal for one week, then two tablets (1000 mg) with the evening meal **S**
- Diclofenac sodium 1% gel, 4 g to each painful knee up to four times a day as needed **S**
- Semaglutide 0.25 mg subcutaneous injection once weekly (starting dose, planned for four weeks) **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 91.5 kg; BMI 35.7 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 91.5 kg, BMI 35.7; blood pressure 124/78, pulse 78 |
| Mouth | Socket of tooth 19 healed; gums red with calculus |
| Feet | Normal 10-g monofilament and vibration sense; dorsalis pedis and posterior tibial pulses present; no callus, ulcer or deformity |
| Knees | Crepitus in both knees; no effusion; full range |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes** (E11.65). Symptoms easing on metformin. Foot examination normal and retinal photographs show no retinopathy. Urine albumin normal at intake. For a woman with obesity and type 2 diabetes the Standards favour a GLP-1 receptor agonist for both glucose and weight; an SGLT2 inhibitor is reserved for kidney disease, heart failure or established cardiovascular disease, none of which she has. She chose semaglutide after hearing the benefits, the common nausea, the rare pancreatitis and gallbladder problems, and that it must be stopped two months before any planned pregnancy. **S**
   - Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg.
   - Small meals, stopping when full.
   - Continue metformin 1000 mg.
   - A1c at about three months.
2. **Obesity, class 2** (E66.812). She raised the subject of her weight herself and set her own goal, to manage stairs more easily. Weight 91.5 kg, down 1.5 kg. **S**
   - Strengthening exercise and protein at each meal to protect muscle and bone as weight falls.
   - Weight recorded only with her permission.
3. **Periodontitis** (K05.323). Socket healed; ready for periodontal therapy. **S**
   - Scaling and root planing with the dental team in two weeks.
4. **Knee osteoarthritis** (M17.0). Better with exercise and topical diclofenac. **S**
   - Continue the exercises; walking goal of 150 minutes a week.
5. **Cardiovascular risk**. Diabetes at 48 with LDL 128 mg/dL, low HDL and high triglycerides; the Standards advise a moderate-intensity statin for adults 40 to 75 with diabetes. ALT normal at baseline. **S**
   - Atorvastatin 20 mg daily.
   - Lipids and ALT at the next review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months until at goal or after a change in therapy, then every six months | Due | 7.6% at diagnosis six weeks ago; next at about three months |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 124/78 |
| Examination | Weight and BMI, recorded with her permission | Every visit | Completed today | 91.5 kg, BMI 35.7 |
| Medication safety | Metformin: dose, tolerance and sick-day rules | Every visit | Completed today | 1000 mg tolerated; sick-day rules reviewed |
| Medication safety | GLP-1 receptor agonist: dose, nausea, warning signs | At start and every visit | Completed today | Semaglutide 0.25 mg weekly started; nausea, pancreatitis, gallbladder and pregnancy advice given |
| Medication safety | Hypoglycemia review | Every visit | Not indicated | Metformin and semaglutide do not cause hypoglycemia on their own |
| Examination | Comprehensive foot examination | At diagnosis, then yearly | Completed today | Normal |
| Imaging | Diabetic eye screening | At diagnosis, then every one to two years | Completed today | Retinal photographs: no retinopathy |
| Laboratory | Urine albumin-to-creatinine ratio and eGFR | At diagnosis, then yearly | Up to date | UACR 18 mg/g and eGFR 103 at intake |
| Laboratory | Lipid panel and ALT on a statin | Baseline, then 4 to 12 weeks after starting a statin | Due | Atorvastatin started today; ALT 31 U/L at baseline; lipids and ALT at the next review |
| Self-management | Diabetes self-management education and nutrition therapy | At diagnosis, then yearly | Completed today | Two of four sessions attended |
| Examination | Dental and periodontal care | At diagnosis, then periodontal maintenance every three months | Completed today | Socket healed; scaling and root planing booked |
| Examination | Knee pain and function | Every visit | Completed today | Better with exercise and gel |

## Goal progress

- Dental infection drained and the tooth removed within 24 hours, with no spread of infection. Outcome by 2026-04-15: Drained and extracted the next day; no spread. **S**
- Hemoglobin A1c below 7% within four months. In progress; target 2026-07-21. **S**
- LDL cholesterol below 100 mg/dL on a statin. In progress; target 2026-07-21. **S**
- Periodontal therapy completed and three-monthly maintenance arranged. In progress; target 2026-07-21. **S**
- Climb stairs at the building sites with less knee pain, and walk 150 minutes a week. In progress; target 2026-07-21. **S**

## Medication changes

- Started: Semaglutide 0.25 mg subcutaneous injection once weekly (starting dose, planned for four weeks) **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (Section 2, Diagnosis and Classification of Diabetes; Section 9, Pharmacologic Approaches to Glycemic Treatment) (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S27-S49 and S183-S215)
- Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 (Section 8) (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S166-S182)
- Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (Section 10) (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S216-S245)
- Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology (2018), European Federation of Periodontology and International Diabetes Federation (J Clin Periodontol 2018;45(2):138-149)
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019), American College of Rheumatology (Arthritis Care Res 2020;72(2):149-162)
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, rheumatoid arthritis and osteoarthritis, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Preventive visit as booked; fourteen-week review with A1c, lipids and ALT. **S**
- Next scheduled visit 2026-06-30: periodic adult preventive visit. **S**
